دورية أكاديمية
أعرض في EDS

Plasma Interleukin-33 Cannot Predict Hip Osteonecrosis in Patients With Sickle Cell Disease: A Case-Control Study.

التفاصيل البيبلوغرافية
العنوان: Plasma Interleukin-33 Cannot Predict Hip Osteonecrosis in Patients With Sickle Cell Disease: A Case-Control Study.
المؤلفون: Agrawal AC; Orthopaedics, All India Institute of Medical Sciences, Raipur, Raipur, IND., Mohapatra E; Biochemistry, All India Institute of Medical Sciences, Raipur, Raipur, IND., Nanda R; Biochemistry, All India Institute of Medical Sciences, Raipur, Raipur, IND., Bodhey NK; Radiodiagnosis, All India Institute of Medical Sciences, Raipur, Raipur, IND., Sakale H; Orthopaedics, All India Institute of Medical Sciences, Raipur, Raipur, IND., Garg AK; Orthopaedics, All India Institute of Medical Sciences, Raipur, Raipur, IND.
المصدر: Cureus [Cureus] 2022 Mar 28; Vol. 14 (3), pp. e23556. Date of Electronic Publication: 2022 Mar 28 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Background Plasma interleukin-33 (IL-33), a cytokine associated with inflammatory and autoimmune disease, has been described to be significantly raised in osteonecrosis of the femoral head (ONFH) and hence was recommended for use as a marker for ONFH. The concentration of plasma interleukin-33 level has not been estimated in any studies conducted in patients with sickle cell disease (SCD); hence, we investigated the levels of plasma interleukin-33 in patients with sickle cell disease with or without ONFH to assess whether it can be used as a marker for the early detection of ONFH in this disease also. Methods Forty-four consecutive patients with sickle cell disease with osteonecrosis of the femoral head and matched controls without ONFH were evaluated for plasma interleukin-33 levels by enzyme-linked immunosorbent assay (ELISA). All patients were confirmed for sickle cell disease using high-performance liquid chromatography (HPLC). ONFH was diagnosed in patients with sickle cell disease using clinical-radiological findings. Univariate and multivariate analyses were performed using the IL-33 level as the dependent variable. Results Plasma IL-33 levels were comparable in 44 patients with sickle cell disease with osteonecrosis of the femoral head as compared with 24 patients with sickle cell disease without ONFH (2.05 ± 4.57 pg/mL versus 1.50 ± 2.89 pg/mL, p-value = 0.590). There was no significant difference in IL-33 levels in different stages of avascular necrosis (AVN). Conclusions Plasma interleukin-33 levels cannot act as a marker of ONFH as were being considered in idiopathic ONFH or ONFH caused by other causes such as trauma and chronic steroid or alcohol usage.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2022, Agrawal et al.)
References: Intrinsically Disord Proteins. 2016 Dec 21;4(1):e1248273. (PMID: 28232898)
Joint Bone Spine. 2011 Dec;78(6):550-4. (PMID: 21703905)
Nat Rev Drug Discov. 2008 Oct;7(10):827-40. (PMID: 18827826)
Semin Arthritis Rheum. 2002 Oct;32(2):94-124. (PMID: 12430099)
Open Orthop J. 2009 May 15;3:32-5. (PMID: 19572037)
J Bone Joint Surg Br. 1992 May;74(3):367-71. (PMID: 1587879)
Indian J Orthop. 2015 Jan-Feb;49(1):28-45. (PMID: 25593355)
Endocrinology. 2011 May;152(5):1911-22. (PMID: 21363931)
Cytokine. 2011 Mar;53(3):347-54. (PMID: 21190867)
J Bone Miner Res. 2011 Apr;26(4):704-17. (PMID: 20939024)
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7. (PMID: 17185418)
Curr Health Sci J. 2009 Jan;35(1):23-8. (PMID: 24778812)
Immunology. 2010 Jun;130(2):172-80. (PMID: 20070408)
J Bone Joint Surg Am. 2012 Jan 18;94(2):156-62. (PMID: 22258003)
Blood Adv. 2017 Jul 11;1(16):1287-1295. (PMID: 29296770)
Rev Bras Hematol Hemoter. 2012;34(2):156-64. (PMID: 23049406)
J Investig Med. 2014 Mar;62(3):635-7. (PMID: 24430213)
Mediators Inflamm. 2017;2017:1732638. (PMID: 28167850)
فهرسة مساهمة: Keywords: avn; hip; osteonecrosis of the femoral head; plasma interleukin-33 level; sickle cell disease
تواريخ الأحداث: Date Created: 20220404 Latest Revision: 20220405
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8971072
DOI: 10.7759/cureus.23556
PMID: 35371856
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.23556